JP2010512315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512315A5 JP2010512315A5 JP2009540288A JP2009540288A JP2010512315A5 JP 2010512315 A5 JP2010512315 A5 JP 2010512315A5 JP 2009540288 A JP2009540288 A JP 2009540288A JP 2009540288 A JP2009540288 A JP 2009540288A JP 2010512315 A5 JP2010512315 A5 JP 2010512315A5
- Authority
- JP
- Japan
- Prior art keywords
- ifnα
- inducible
- activity
- expression profile
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 21
- 230000000694 effects Effects 0.000 claims 11
- 239000003550 marker Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims 3
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 claims 3
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims 3
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 claims 3
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims 3
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims 3
- 101000657037 Homo sapiens Radical S-adenosyl methionine domain-containing protein 2 Proteins 0.000 claims 3
- 101000880044 Homo sapiens SLIT-ROBO Rho GTPase-activating protein 3 Proteins 0.000 claims 3
- 101000822540 Homo sapiens Sterile alpha motif domain-containing protein 9-like Proteins 0.000 claims 3
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 claims 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims 3
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims 3
- 102100033749 Radical S-adenosyl methionine domain-containing protein 2 Human genes 0.000 claims 3
- 102100037372 SLIT-ROBO Rho GTPase-activating protein 2 Human genes 0.000 claims 3
- 102100022459 Sterile alpha motif domain-containing protein 9-like Human genes 0.000 claims 3
- 102100039488 XIAP-associated factor 1 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 201000002481 Myositis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 239000003124 biologic agent Substances 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 230000003827 upregulation Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87300806P | 2006-12-06 | 2006-12-06 | |
| US90776207P | 2007-04-16 | 2007-04-16 | |
| US90776707P | 2007-04-16 | 2007-04-16 | |
| US92421907P | 2007-05-03 | 2007-05-03 | |
| US92422007P | 2007-05-03 | 2007-05-03 | |
| US92458407P | 2007-05-21 | 2007-05-21 | |
| US96018707P | 2007-09-19 | 2007-09-19 | |
| US99617407P | 2007-11-05 | 2007-11-05 | |
| US99617607P | 2007-11-05 | 2007-11-05 | |
| US99621907P | 2007-11-06 | 2007-11-06 | |
| US99682007P | 2007-12-06 | 2007-12-06 | |
| PCT/US2007/024941 WO2008070135A2 (en) | 2006-12-06 | 2007-12-06 | Methods of treating systemic lupus erythematosus |
| PCT/US2007/024947 WO2008070137A2 (en) | 2006-12-06 | 2007-12-06 | Interferon alpha-induced pharmacodynamic markers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183939A Division JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512315A JP2010512315A (ja) | 2010-04-22 |
| JP2010512315A5 true JP2010512315A5 (https=) | 2011-01-20 |
Family
ID=39492862
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540288A Pending JP2010512315A (ja) | 2006-12-06 | 2007-12-06 | インターフェロンα誘導性薬力学的マーカー |
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540285A Pending JP2010512313A (ja) | 2006-12-06 | 2007-12-06 | 全身性エリテマトーデスの治療方法 |
| JP2013183939A Pending JP2014014370A (ja) | 2006-12-06 | 2013-09-05 | インターフェロンα誘導性薬力学的マーカー |
| JP2013193959A Pending JP2014040430A (ja) | 2006-12-06 | 2013-09-19 | 全身性エリテマトーデスの治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20100143373A1 (https=) |
| EP (3) | EP2077858A4 (https=) |
| JP (4) | JP2010512315A (https=) |
| KR (2) | KR20090088932A (https=) |
| AU (2) | AU2007327993B2 (https=) |
| BR (2) | BRPI0720035A2 (https=) |
| CA (2) | CA2670594A1 (https=) |
| MX (1) | MX2009005787A (https=) |
| RU (2) | RU2527068C2 (https=) |
| WO (2) | WO2008070135A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| EP2076590A4 (en) * | 2007-05-03 | 2011-06-01 | Medimmune Llc | SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS |
| ES2542836T3 (es) * | 2007-07-12 | 2015-08-12 | The Brigham And Women's Hospital, Inc. | Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias |
| PT2219452E (pt) | 2007-11-05 | 2016-01-26 | Medimmune Llc | Métodos de tratamento de esclerodermia |
| SG188147A1 (en) * | 2008-02-08 | 2013-03-28 | Medimmune Llc | Disease markers and uses thereof |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| US20120251546A1 (en) * | 2009-09-03 | 2012-10-04 | Medimmune Llc | Type 1 inteferon diagnostic |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US9709565B2 (en) | 2010-04-21 | 2017-07-18 | Memed Diagnostics Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
| US20130317040A1 (en) * | 2010-12-22 | 2013-11-28 | The Feinstein Institute Of Medical Research | Methods for treating systemic lupus erythematosus using hiv protease inhibitors |
| AU2012249601A1 (en) * | 2011-04-26 | 2013-05-09 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| AU2013204880B2 (en) * | 2011-04-26 | 2016-11-24 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| GB201115665D0 (en) | 2011-09-09 | 2011-10-26 | Univ Leuven Kath | Autoimmune and inflammatory disorder therapy |
| MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
| WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| EP3367099B1 (en) | 2012-02-09 | 2021-05-26 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| US20150168398A1 (en) | 2012-05-17 | 2015-06-18 | The Johns Hopkins University | Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy |
| AU2013274389A1 (en) * | 2012-06-13 | 2015-01-22 | Astrazeneca Ab | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| US20140156297A1 (en) * | 2012-08-03 | 2014-06-05 | Axelacare Holdings, Inc. | Computer program, method, and system for pharmacist-assisted treatment of patients |
| US20140039907A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for collecting patient data with a portable electronic device |
| US20140275257A1 (en) * | 2013-03-14 | 2014-09-18 | Foundation for the State University of New York | N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus |
| BR112017002884A2 (pt) | 2014-08-14 | 2018-01-30 | Memed Diagnostics Ltd | ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano? |
| CN105420347A (zh) * | 2014-08-21 | 2016-03-23 | 南京大学医学院附属鼓楼医院 | 一种用于系统性红斑狼疮的基因诊断试剂盒 |
| US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| CN111624345A (zh) | 2014-12-11 | 2020-09-04 | 米密德诊断学有限公司 | 用于诊断多种感染的标记组合及其使用方法 |
| IL287757B (en) | 2016-03-03 | 2022-07-01 | Memed Diagnostics Ltd | Analyzing rna for diagnosing infection type |
| EP3423590A4 (en) | 2016-03-03 | 2020-02-26 | Memed Diagnostics Ltd. | DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS |
| EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| EP3482200B1 (en) | 2016-07-10 | 2022-05-04 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| WO2018060999A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| WO2018112464A1 (en) * | 2016-12-16 | 2018-06-21 | The Penn State Research Foundation | Methods for improved reproductive management of ruminant ungulates |
| WO2018136625A2 (en) * | 2017-01-20 | 2018-07-26 | Children's Medical Center Corporation | Compositions and methods for treating diseases characterized by reactive microglia mediated synapse loss |
| US10209260B2 (en) | 2017-07-05 | 2019-02-19 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| US11926664B2 (en) | 2017-07-25 | 2024-03-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating monocytopoiesis |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EA202191133A1 (ru) * | 2018-10-26 | 2021-07-12 | Янссен Байотек, Инк. | Сигнатуры интерферона типа i и способы их применения |
| WO2020117715A1 (en) | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
| EP3924383A1 (en) | 2019-02-15 | 2021-12-22 | Astrazeneca AB | Type i interferon-mediated disorders |
| US12011284B2 (en) * | 2020-05-19 | 2024-06-18 | Peachy Corp. | Systems and methods for preventing and treating wrinkles |
| KR102429261B1 (ko) | 2020-08-25 | 2022-08-03 | 충북대학교 산학협력단 | 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커 |
| AR123650A1 (es) * | 2020-10-02 | 2022-12-28 | Celgene Corp | Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias |
| HRP20231255T1 (hr) | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| KR20240023602A (ko) | 2021-06-18 | 2024-02-22 | 아이오니스 파마수티컬즈, 인코포레이티드 | Ifnar1 발현을 감소시키기 위한 화합물 및 방법 |
| FR3138815A1 (fr) * | 2022-08-12 | 2024-02-16 | bioMérieux | Détermination de la nature virale ou bactérienne d’une infection |
| CN117305441B (zh) * | 2023-10-13 | 2025-04-08 | 福建农林大学 | 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法 |
| WO2025213238A1 (en) * | 2024-04-12 | 2025-10-16 | HaemaLogiX Ltd | Anti-kma antibody formulations |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| FR2692168B1 (fr) | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5972901A (en) | 1994-03-23 | 1999-10-26 | Case Western Reserve University | Serpin enzyme complex receptor--mediated gene transfer |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| JP4285766B2 (ja) | 1994-03-23 | 2009-06-24 | オハイオ ユニバーシティ | 緻密にした核酸および細胞へのデリバリ |
| US6905587B2 (en) * | 1996-03-22 | 2005-06-14 | Ronald Redline | Method for enhancing the solderability of a surface |
| AU749032B2 (en) | 1997-06-13 | 2002-06-20 | Johns Hopkins University, The | Therapeutic nanospheres |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20050008683A1 (en) * | 2000-06-29 | 2005-01-13 | Becton Dickinson And Company | Method for delivering interferons to the intradermal compartment |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003046008A1 (en) * | 2001-11-30 | 2003-06-05 | Innogenetics N.V. | Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| EP2298360A3 (en) * | 2002-11-21 | 2011-07-13 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| CN1871252A (zh) * | 2003-09-05 | 2006-11-29 | Gtc生物治疗学公司 | 在转基因哺乳动物奶中生产融合蛋白的方法 |
| NZ547157A (en) * | 2003-12-10 | 2009-07-31 | Medarex Inc | Interferon Alpha Antibodies and their uses |
| HUE035082T2 (en) * | 2004-06-21 | 2018-05-02 | Squibb & Sons Llc | Interferon alpha receptor 1 antibodies and their use |
| US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| US7833795B2 (en) * | 2004-08-24 | 2010-11-16 | The Trustees Of The University Of Pennsylvania | Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors |
| US7571055B2 (en) * | 2004-10-13 | 2009-08-04 | Regents Of The University Of Minnesota | Systemic lupus erythematosus |
| WO2006086586A2 (en) * | 2005-02-10 | 2006-08-17 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US20070117105A1 (en) * | 2005-05-12 | 2007-05-24 | Crow Mary K | Interferon assay |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| PT2327792E (pt) * | 2005-08-05 | 2013-11-21 | Genentech Inc | Métodos e composições para a detecção de distúrbios autoimunes |
| US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| EP2057190A4 (en) * | 2006-08-09 | 2010-07-28 | Baylor Res Inst | MONOCLONAL ANTI-INTERFERON ALPHA ANTIBODIES AND USE METHOD THEREFOR |
| EP2077858A4 (en) * | 2006-12-06 | 2011-07-20 | Medimmune Llc | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS |
| CA2682292A1 (en) * | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Aqueous formulation comprising an anti-human interferon alpha antibody |
| US20120251546A1 (en) * | 2009-09-03 | 2012-10-04 | Medimmune Llc | Type 1 inteferon diagnostic |
-
2007
- 2007-12-06 EP EP07867637A patent/EP2077858A4/en not_active Ceased
- 2007-12-06 AU AU2007327993A patent/AU2007327993B2/en not_active Ceased
- 2007-12-06 US US12/517,334 patent/US20100143373A1/en not_active Abandoned
- 2007-12-06 US US12/517,333 patent/US20100143372A1/en not_active Abandoned
- 2007-12-06 RU RU2009125616/10A patent/RU2527068C2/ru not_active IP Right Cessation
- 2007-12-06 AU AU2007327995A patent/AU2007327995B2/en not_active Ceased
- 2007-12-06 JP JP2009540288A patent/JP2010512315A/ja active Pending
- 2007-12-06 WO PCT/US2007/024941 patent/WO2008070135A2/en not_active Ceased
- 2007-12-06 EP EP13179923.1A patent/EP2712930A3/en not_active Withdrawn
- 2007-12-06 KR KR1020097013891A patent/KR20090088932A/ko not_active Ceased
- 2007-12-06 CA CA002670594A patent/CA2670594A1/en not_active Abandoned
- 2007-12-06 BR BRPI0720035-8A patent/BRPI0720035A2/pt active Search and Examination
- 2007-12-06 BR BRPI0719912-0A2A patent/BRPI0719912A2/pt not_active IP Right Cessation
- 2007-12-06 WO PCT/US2007/024947 patent/WO2008070137A2/en not_active Ceased
- 2007-12-06 EP EP07867634A patent/EP2073844A4/en not_active Ceased
- 2007-12-06 JP JP2009540285A patent/JP2010512313A/ja active Pending
- 2007-12-06 MX MX2009005787A patent/MX2009005787A/es active IP Right Grant
- 2007-12-06 KR KR1020097013872A patent/KR101532797B1/ko not_active Expired - Fee Related
- 2007-12-06 CA CA002670897A patent/CA2670897A1/en not_active Abandoned
-
2013
- 2013-09-05 JP JP2013183939A patent/JP2014014370A/ja active Pending
- 2013-09-19 JP JP2013193959A patent/JP2014040430A/ja active Pending
-
2014
- 2014-07-03 RU RU2014127178A patent/RU2014127178A/ru not_active Application Discontinuation
- 2014-07-14 US US14/330,609 patent/US20150044222A1/en not_active Abandoned
-
2015
- 2015-01-27 US US14/606,832 patent/US20150147336A1/en not_active Abandoned
-
2016
- 2016-10-11 US US15/290,925 patent/US20170121771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010512315A5 (https=) | ||
| JP2010527917A5 (https=) | ||
| Powell et al. | Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response | |
| Ouyang et al. | Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis | |
| RU2014127178A (ru) | Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006 | |
| Conti et al. | Biomarkers to personalize the treatment of rheumatoid arthritis: focus on autoantibodies and pharmacogenetics | |
| WO2016062101A1 (zh) | 检测ndm-1的修饰电极及其制备方法和应用 | |
| NZ590988A (en) | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders | |
| Qasem et al. | Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease | |
| JP2013178260A5 (https=) | ||
| Ravi et al. | A GMR-based assay for quantification of the human response to influenza | |
| Kadasah et al. | Tumor necrosis factor-α and-β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia | |
| Liu et al. | Functional effect of polymorphisms in the promoter of TNFAIP3 (A20) in acute pancreatitis in the Han Chinese population | |
| Backes et al. | Influence of next-generation sequencing and storage conditions on miRNA patterns generated from PAXgene blood | |
| Hussain et al. | CCL2/MCP-I genotype-phenotype relationship in latent tuberculosis infection | |
| Sun et al. | Downregulation of microRNA‐101‐3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9 | |
| Mahmood et al. | The pncA gene mutations of Mycobacterium tuberculosis in multidrug‐resistant tuberculosis | |
| CN103820545B (zh) | 用于检测人abcg2基因突变的探针、引物及试剂盒 | |
| CN104120172B (zh) | 精神分裂症的基因标志物及其使用方法和应用 | |
| Moraes Holst et al. | Downregulated mucosal autophagy, alpha kinase-1 and IL-17 signaling pathways in active and quiescent ulcerative colitis | |
| JP2015502137A5 (https=) | ||
| CN102787161B (zh) | 一种检测结核分枝杆菌方法及其专用引物 | |
| Angata et al. | Association of serum interleukin‐27 with the exacerbation of chronic obstructive pulmonary disease | |
| Troudet et al. | Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses | |
| WO2023004203A1 (en) | Use of genetic and epigenetic markers to detect cell death |